SEC Form 5 · accession 0001209191-18-010227
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alfred D Kingsley
Officer — See Remarks · Director
Period of report
Dec 31, 2017
Accepted (ET)
Feb 14, 2018 · 9:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, no par valueF1,F2 | Oct 1, 2017 | G | 10,000 | — | D | 5,471,555 | D | |
| Common Shares, no par valueF3 | Dec 1, 2017 | G | 100,000 | — | D | 1,043,346 | I | By Greenbelt Corp. |
| Common Shares, no par value | holding | — | — | — | 375,351 | I | By Greenway Partners, LP |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common SharesF4 | $4.13 | holding | — | — | — | — | Jun 30, 2018 | Common Shares | 50,000 | 50,000 | D |
| Option to Purchase Common SharesF5 | $3.11 | holding | — | — | — | — | Jun 30, 2019 | Common Shares | 50,000 | 50,000 | D |
| Option to Purchase Common SharesF6 | $3.57 | holding | — | — | — | — | Jun 30, 2020 | Common Shares | 50,000 | 50,000 | D |
| Option to Purchase Common SharesF7 | $2.72 | holding | — | — | — | — | Jun 30, 2021 | Common Shares | 50,000 | 50,000 | D |
| Option to Purchase Common SharesF8 | $3.15 | holding | — | — | — | — | Jun 30, 2022 | Common Shares | 50,000 | 50,000 | D |
Explanation of responses
- F1During October 2017, Mr. Kingsley gifted a total of 10,000 common shares.
- F2Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.
- F3During December 2017, Greenbelt Corp. gifted a total of 100,000 common shares to certain charitable organizations.
- F412,500 options became exercisable on September 30, 2013; December 31, 2013; March 31, 2014; and June 30, 2014.
- F512,500 options became exercisable on September 30, 2014; December 31, 2014; March 31, 2015, and June 30, 2015.
- F612,500 options became exercisable on September 30, 2015; December 31, 2015; March 31, 2016; and June 30, 2016.
- F712,500 options became exercisable on September 30, 2016; December 31, 2016; March 31, 2017; and June 30, 2017.
- F812,500 options became exercisable on September 30, 2017 and December 31, 2017, and the remaining 25,000 options will become exercisable in 2 equal quarterly installments based upon continued service on the board of directors.
Remarks
Mr. Kingsley is Executive Chairman of certain BioTime subsidiaries.